Lipoprotein disorders classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 17: Line 17:
|-
|-
   ! Type I
   ! Type I
   | Buerger-Gruetz syndrome, Primary hyperlipoproteinaemia, or Familial hyperchylomicronemia
   | Buerger-Gruetz syndrome, primary hyperlipoproteinaemia, or [[familial hyperchylomicronemia]]
   | Decreased [[lipoprotein lipase]] (LPL) or altered [[apolipoprotein C2|ApoC2]]
   | Decreased [[lipoprotein lipase]] (LPL) or altered [[apolipoprotein C2|ApoC2]]
   | Elevated [[Chylomicrons]]
   | Elevated [[Chylomicrons|chylomicrons]]
   | Diet Control
   | Diet control
|-
|-
   ! Type IIa
   ! Type IIa
   | Polygenic hypercholesterolaemia or [[Familial hypercholesterolemia]]
   | Polygenic hypercholesterolaemia or familial hypercholesterolemia
   | [[LDL receptor]] deficiency
   | [[LDL receptor]] deficiency
   | Elevated [[LDL]] only
   | Elevated [[LDL]] only
   | Bile Acid Sequestrants, [[Statin]]s, [[Niacin]]
   | Bile acid sequestrants, [[statin]]s, [[niacin]]
|-
|-
   ! Type IIb
   ! Type IIb
   | [[Combined hyperlipidemia]]
   | [[Combined hyperlipidemia]]
   | Decreased [[LDL receptor]] and Increased [[apolipoprotein B|ApoB]]
   | Decreased [[LDL receptor]] and increased [[apolipoprotein B|ApoB]]
   | Elevated [[LDL]], [[VLDL]] and Triglycerides
   | Elevated [[LDL]], [[VLDL]] and triglycerides
   | [[Statin]]s, [[Niacin]], [[Gemfibrozil]]
   | [[Statin]]s, [[Niacin]], [[Gemfibrozil]]
|-
|-
Line 42: Line 42:
   ! Type IV
   ! Type IV
   | Endogenous Hyperlipemia
   | Endogenous Hyperlipemia
   | Increased [[VLDL]] production and Decreased elimination
   | Increased [[VLDL]] production and decreased elimination
   | Increased [[VLDL]]
   | Increased [[VLDL]]
   | Drug of choice: [[Niacin]]
   | Drug of choice: [[Niacin]]
Line 48: Line 48:
   ! Type V
   ! Type V
   | Familial Hypertriglyceridemia
   | Familial Hypertriglyceridemia
   | Increased [[VLDL]] production and Decreased [[LPL]]
   | Increased [[VLDL]] production and decreased [[LPL]]
   | Increased [[VLDL]] and [[Chylomicrons]]
   | Increased [[VLDL]] and [[Chylomicrons]]
   | [[Niacin]], [[Gemfibrozil]]
   | [[Niacin]], [[Gemfibrozil]]

Revision as of 13:18, 11 June 2013

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Lipoprotein Disorders Microchapters

Patient Information

Overview

Causes

Classification

Hyperlipoproteinemia
Hypolipoproteinemia

Treatment

Overview

Hyperlipidemias are classified according to the Fredrickson classification which is based on the pattern of lipoproteins on electrophoresis or ultracentrifugation.[1] It was later adopted by the World Health Organization (WHO). It does not directly account for HDL, and it does not distinguish among the different genes that may be partially responsible for some of these conditions. It remains a popular system of classification, but is considered dated by many.

Classification

Fredrickson classification of Hyperlipidemias
Hyperlipoproteinemia Synonyms Problems Labs description Treatment
Type I Buerger-Gruetz syndrome, primary hyperlipoproteinaemia, or familial hyperchylomicronemia Decreased lipoprotein lipase (LPL) or altered ApoC2 Elevated chylomicrons Diet control
Type IIa Polygenic hypercholesterolaemia or familial hypercholesterolemia LDL receptor deficiency Elevated LDL only Bile acid sequestrants, statins, niacin
Type IIb Combined hyperlipidemia Decreased LDL receptor and increased ApoB Elevated LDL, VLDL and triglycerides Statins, Niacin, Gemfibrozil
Type III Familial Dysbetalipoproteinemia Defect in ApoE synthesis Increased IDL Drug of choice: Gemfibrozil
Type IV Endogenous Hyperlipemia Increased VLDL production and decreased elimination Increased VLDL Drug of choice: Niacin
Type V Familial Hypertriglyceridemia Increased VLDL production and decreased LPL Increased VLDL and Chylomicrons Niacin, Gemfibrozil

Unclassified forms

Non-classified forms are extremely rare:

  • Hypo-alpha lipoproteinemia
  • Hypo-beta lipoproteinemia (prevalence 0.01-0.1%)

References

  1. Frederickson DS, Lee RS. A system for phenotyping hyperlipidemia. Circulation 1965;31:321-7. PMID 14262568.

External links

Template:Metabolic pathology

de:Hyperlipoproteinämie he:היפרליפידמיה sv:Hyperlipidemi


Template:WikiDoc Sources